CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Pioneering protease-based masking of therapeutic antibodies and biologics, particularly in oncology Key Points Colorectal Cancer Data - **Product**: CX2051, an antibody-drug conjugate (ADC) targeting EpCAM, specifically designed for late-line colorectal cancer (CRC) treatment [2][3] - **Phase 1 Data**: Initial data showed a 28% confirmed response rate in late-stage CRC patients with a median of four prior therapies [4][10] - **Patient Enrollment**: Expanded from 25 to 100 patients in the phase 1 study, with a focus on evaluating 73 to 100 patients for efficacy [5][10] Dose Escalation and Safety - **Dose Levels**: Current doses being evaluated are 7.2, 8.6, and 10 mg/kg, with no dose-limiting toxicities (DLTs) reported to date [9][10] - **Response Rate Expectations**: Current treatment options for late-stage CRC have low response rates; CytomX aims to demonstrate superior efficacy with CX2051 [10][11] Future Development Plans - **Next Steps**: Plans to initiate a combination study with bevacizumab (Bev) in Q1 2026, and potentially a registrational study in the fourth line of therapy against fruquintinib [13][14] - **Additional Indications**: Exploring the use of CX2051 in other solid tumors, including gastric and pancreatic cancers, as EpCAM is highly expressed in these types [15] Competitive Landscape - **Market Position**: CX2051 is the first anti-EpCAM ADC developed, with other competitors in the topo-based ADC space showing promise but not matching the initial data from CytomX [18][20] Other Programs - **CX-801 Program**: A masked interferon alpha-2b designed to enhance the immune response while minimizing systemic side effects, with plans for combination studies with Keytruda in late-stage melanoma [21][22] - **Therapeutic Window**: The goal is to improve tolerability and efficacy of established therapies through innovative masking technology [23] Data Presentation - **Upcoming Data Reveal**: Anticipated updates on the 100 patient study in Q1 2026, with a focus on determining optimal dosing and safety profiles [25][26] Conclusion CytomX Therapeutics is positioned to make significant advancements in the treatment of colorectal cancer and other solid tumors through its innovative ADC technology and strategic development plans. The company is actively expanding its clinical trials and exploring new indications, while maintaining a competitive edge in the oncology market.